Phenominer

Phenominer Database Results (111 results)

Colored By:

DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))
DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))
gene transfer using empty plasmid vector pVAX2 (30 ug) and gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2)
DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))
DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2)
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))
DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))
DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))
DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))
gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (4 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2)
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))
DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))
gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (40 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2)
vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2)
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))
DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))
DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))
gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2)
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2)
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))
control condition then controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd x s/m2)
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))
gene transfer of the lin-28 homolog B gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours)
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))
lensotomy then controlled exposure to darkness (for 1 days) then visible light stimulus (100 cd x s/m2)
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2)
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))
DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))
DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))
DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))
DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))
controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2)
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))
control condition then controlled exposure to darkness (for 12 hours)
gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours)
gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (21.6 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd x s/m2)

Table "column sort" updates the order of the bars in the chart.

Strain	Phenotype	Conditions	Study	Experiment Name	Sex	Age	# of Animals	Value	Units	SEM	SD	Method	Method Site	Post Insult Type	Post Insult Time Value	Post Insult Time Unit	Method Notes	Clinical Measurement Notes	Record ID	Study ID
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	241.17	uV	16.89	41.37	electroretinography	cornea	subretinal injection	2	days	dl-aaa + MPEP	a-wave amplitude ERG	108517	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	57.63	uV	8.8	21.56	electroretinography	cornea	subretinal injection	2	days	dl-aaa + pbs	a-wave amplitude ERG	108520	3123
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	39 days	7	11.45	uV	3.56	9.42	electroretinography	cornea	subretinal injection	4	days	MPEP	a-wave amplitude ERG	108537	3123
Hsd:SD	scotopic A wave amplitude of ERG waveform	gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (40 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2)	Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.	rod electrophysiology trait	both	0 days	9	173.0	uV			electroretinography	cornea	subretinal injection	30	days		scotopic a-wave ERG	108654	3128
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours)	Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343.	rod electrophysiology trait	both	34 days	8	20.0	uV	20.0	56.57	electroretinography	cornea	subretinal injection	14	days	adenovirus	a-wave amplitude ERG	108375	3121
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	8.81	uV	1.84	4.51	electroretinography	cornea	subretinal injection	7	days	dl-aaa	a-wave amplitude ERG	108392	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	25.3	uV	2.85	6.98	electroretinography	cornea	subretinal injection	7	days	dl-aaa	a-wave amplitude ERG	108399	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	161.92	uV	30.48	74.66	electroretinography	cornea	subretinal injection	7	days	dl-aaa	a-wave amplitude ERG	108401	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	94.57	uV	13.87	33.97	electroretinography	cornea	subretinal injection	10	days	dl-aaa	a-wave amplitude ERG	108424	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	243.17	uV	24.11	59.06	electroretinography	cornea	subretinal injection	10	days	dl-aaa	a-wave amplitude ERG	108427	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	201.67	uV	18.19	44.56	electroretinography	cornea	subretinal injection	30	min	CHPG	a-wave amplitude ERG	108444	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	26.68	uV	7.67	18.79	electroretinography	cornea	subretinal injection	30	min	pbs	a-wave amplitude ERG	108447	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	190.83	uV	21.76	53.3	electroretinography	cornea	subretinal injection	30	min	pbs	a-wave amplitude ERG	108450	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	11	87.05	uV	8.87	29.42	electroretinography	cornea	subretinal injection	2	days	pbs	a-wave amplitude ERG	108472	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	206.0	uV	11.62	28.46	electroretinography	cornea	subretinal injection	10	days	pbs	a wave amplitude ERG	108499	3123
Hsd:SD	scotopic A wave amplitude of ERG waveform	gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (4 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2)	Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.	rod electrophysiology trait	both	0 days	9	154.0	uV			electroretinography	cornea	subretinal injection	30	days		scotopic a-wave ERG	108648	3128
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	39 days	7	5.86	uV	0.76	2.01	electroretinography	cornea	subretinal injection	4	days	MPEP	a-wave amplitude ERG	108536	3123
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	39 days	7	27.22	uV	4.74	12.54	electroretinography	cornea	subretinal injection	4	days	MPEP	a-wave amplitude ERG	108539	3123
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	39 days	7	33.73	uV	9.28	24.55	electroretinography	cornea	subretinal injection	4	days	MPEP	a-wave amplitude ERG	108540	3123
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	39 days	7	15.31	uV	2.98	7.88	electroretinography	cornea	subretinal injection	4	days	MPEP	a-wave amplitude ERG	108549	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	16.12	uV	3.84	9.41	electroretinography	cornea	subretinal injection	2	days	dl-aaa + MPEP	a-wave amplitude ERG	108512	3123
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2)	Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.	rod electrophysiology trait	both	53 days	5	96.3	uV	10.3	23.03	electroretinography	cornea	plasmid delivery	37	days	pVAX2-rGDNF	scotopic a-wave ERG	108725	3131
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2)	Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.	rod electrophysiology trait	both	75 days	5	29.7	uV	11.3	25.27	electroretinography	cornea	plasmid delivery	59	days	pVAX2-rGDNF	scotopic a-wave ERG	108729	3131
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	78.43	uV	13.51	33.09	electroretinography	cornea	subretinal injection	7	days	dl-aaa	a-wave amplitude ERG	108394	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	118.43	uV	17.52	42.92	electroretinography	cornea	subretinal injection	7	days	dl-aaa	a-wave amplitude ERG	108396	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	9.73	uV	2.39	5.85	electroretinography	cornea	subretinal injection	7	days	dl-aaa	a-wave amplitude ERG	108398	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	109.52	uV	22.74	55.7	electroretinography	cornea	subretinal injection	7	days	dl-aaa	a-wave amplitude ERG	108400	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	23.02	uV	5.24	12.84	electroretinography	cornea	subretinal injection	10	days	dl-aaa	a-wave amplitude ERG	108417	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	6.38	uV	1.4	3.43	electroretinography	cornea	subretinal injection	30	min	CHPG	a-wave amplitude ERG	108440	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	155.28	uV	13.68	33.51	electroretinography	cornea	subretinal injection	30	min	CHPG	a-wave amplitude ERG	108443	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	8.38	uV	1.81	4.43	electroretinography	cornea	subretinal injection	30	min	pbs	a-wave amplitude ERG	108446	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	78.77	uV	13.41	32.85	electroretinography	cornea	subretinal injection	30	min	pbs	a-wave amplitude ERG	108448	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	146.78	uV	16.49	40.39	electroretinography	cornea	subretinal injection	30	min	pbs	a-wave amplitude ERG	108449	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	11	12.43	uV	2.29	7.6	electroretinography	cornea	subretinal injection	2	days	pbs	a-wave amplitude ERG	108470	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	11	18.46	uV	3.3	10.94	electroretinography	cornea	subretinal injection	2	days	pbs	a-wave amplitude ERG	108471	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	11	144.39	uV	13.24	43.91	electroretinography	cornea	subretinal injection	2	days	pbs	a-wave amplitude ERG	108473	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	80.6	uV	11.3	27.68	electroretinography	cornea	subretinal injection	10	days	CHPG	a-wave amplitude ERG	108490	3123
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours)	Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343.	rod electrophysiology trait	both	62 days	5	9.7	uV	9.9	22.14	electroretinography	cornea	subretinal injection	42	days	adenovirus	a-wave amplitude ERG	108387	3121
RCS/N	scotopic A wave amplitude of ERG waveform	lensotomy then controlled exposure to darkness (for 1 days) then visible light stimulus (100 cd x s/m2)	Heiduschka P, et al., ISRN Ophthalmol. 2013 Sep 19;2013:814814. doi: 10.1155/2013/814814. eCollection 2013.	rod electrophysiology trait	not specified	60 days	3	18.3	uV	4.79	8.3	electroretinography	cornea	lens puncture	30	days		scotopic a-wave ERG	108566	3124
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	39 days	7	31.22	uV	8.16	21.59	electroretinography	cornea	subretinal injection	4	days	MPEP	a-wave amplitude ERG	108551	3123
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2)	Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.	rod electrophysiology trait	both	87 days	5	24.5	uV	4.9	10.96	electroretinography	cornea	plasmid delivery	71	days		scotopic a-wave ERG	108734	3131
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	19.36	uV	3.48	8.52	electroretinography	cornea	subretinal injection	2	days	dl-aaa + MPEP	a-wave amplitude ERG	108513	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	16.61	uV	4.28	10.48	electroretinography	cornea	subretinal injection	2	days	dl-aaa + pbs	a-wave amplitude ERG	108518	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	89.88	uV	11.06	27.09	electroretinography	cornea	subretinal injection	2	days	dl-aaa + pbs	a-wave amplitude ERG	108521	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	124.83	uV	7.26	17.78	electroretinography	cornea	subretinal injection	2	days	dl-aaa + pbs	a-wave amplitude ERG	108522	3123
Hsd:SD	scotopic A wave amplitude of ERG waveform	controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2)	Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.	rod electrophysiology trait	both	0 days	9	203.0	uV			electroretinography	cornea		0			scotopic a-wave ERG	108655	3128
RCS/N	scotopic A wave amplitude of ERG waveform	control condition then controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd x s/m2)	Deng WT, et al., Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904. doi: 10.1167/iovs.11-8831.	rod electrophysiology trait	not specified	62 days	6	16.0	uV	6.94	17.0	electroretinography	cornea	AAV8 injection	60	days	contralateral control eye	scotopic a-wave amplitude ERG	108681	3129
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	gene transfer using empty plasmid vector pVAX2 (30 ug) and gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2)	Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.	rod electrophysiology trait	both	70 days	3	23.8	uV	1.9	3.29	electroretinography	cornea	plasmid delivery	54	days	pVAX2	scotopic a-wave ERG	108746	3131
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	11.22	uV	1.07	2.62	electroretinography	cornea	subretinal injection	10	days	dl-aaa	a-wave amplitude ERG	108416	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	95.25	uV	7.15	17.51	electroretinography	cornea	subretinal injection	10	days	dl-aaa	a-wave amplitude ERG	108418	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	240.67	uV	14.84	36.35	electroretinography	cornea	subretinal injection	10	days	dl-aaa	a-wave amplitude ERG	108421	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	25.21	uV	4.23	10.36	electroretinography	cornea	subretinal injection	30	min	CHPG	a-wave amplitude ERG	108441	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	11	11.68	uV	2.42	8.03	electroretinography	cornea	subretinal injection	2	days	CHPG	a-wave amplitude ERG	108465	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	11	104.17	uV	12.63	41.89	electroretinography	cornea	subretinal injection	2	days	CHPG	a-wave amplitude ERG	108467	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	11	118.51	uV	12.59	41.76	electroretinography	cornea	subretinal injection	2	days	CHPG	a-wave amplitude ERG	108468	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	24.73	uV	6.11	14.97	electroretinography	cornea	subretinal injection	10	days	CHPG	a-wave amplitude ERG	108489	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	119.33	uV	19.43	47.59	electroretinography	cornea	subretinal injection	10	days	CHPG	a-wave amplitude ERG	108491	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	13.98	uV	3.06	7.5	electroretinography	cornea	subretinal injection	10	days	pbs	a wave amplitude ERG	108494	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	145.83	uV	14.32	35.08	electroretinography	cornea	subretinal injection	10	days	pbs	a wave amplitude ERG	108497	3123
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	control condition then controlled exposure to darkness (for 12 hours)	Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343.	rod electrophysiology trait	both	34 days	8	13.0	uV	13.0	36.77	electroretinography			0		untreated control	electrical activity measurement of retina (CMO:0003653)/A wave	108374	3121
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	control condition then controlled exposure to darkness (for 12 hours)	Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343.	rod electrophysiology trait	both	48 days	5	17.0	uV	5.0	11.18	electroretinography			0		untreated control	a-wave amplitude ERG	108380	3121
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	gene transfer of the lin-28 homolog B gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours)	Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343.	rod electrophysiology trait	both	34 days	8	34.0	uV	26.0	73.54	electroretinography	cornea	subretinal injection	14	days	adenovirus	a-wave amplitude ERG	108376	3121
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	gene transfer of the lin-28 homolog B gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours)	Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343.	rod electrophysiology trait	both	48 days	5	27.0	uV	22.0	49.19	electroretinography	cornea	subretinal injection	28	days	adenovirus	a-wave amplitude ERG	108382	3121
Hsd:SD	scotopic A wave amplitude of ERG waveform	controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2)	Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.	rod electrophysiology trait	both	0 days	9	195.0	uV			electroretinography	cornea		0			scotopic a-wave ERG	108649	3128
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	172.6	uV	20.12	49.28	electroretinography	cornea	subretinal injection	2	days	dl-aaa + MPEP	a-wave amplitude ERG	108515	3123
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	39 days	7	19.05	uV	3.75	9.92	electroretinography	cornea	subretinal injection	4	days	MPEP	a-wave amplitude ERG	108550	3123
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2)	Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.	rod electrophysiology trait	both	87 days	5	17.1	uV	3.2	7.16	electroretinography	cornea	plasmid delivery	71	days	pVAX2-rGDNF	scotopic a-wave ERG	108733	3131
Hsd:SD	scotopic A wave amplitude of ERG waveform	vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2)	Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.	rod electrophysiology trait	both	0 days	4	142.0	uV			electroretinography	cornea	subretinal injection	30	days		scotopic a-wave ERG	108642	3128
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2)	Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.	rod electrophysiology trait	both	53 days	5	60.2	uV	8.5	19.01	electroretinography	cornea	plasmid delivery	37	days		scotopic a-wave ERG	108726	3131
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2)	Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.	rod electrophysiology trait	both	70 days	3	26.7	uV	2.7	4.68	electroretinography	cornea	plasmid delivery	54	days	pVAX2-rGDNF	scotopic a-wave ERG	108747	3131
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2)	Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.	rod electrophysiology trait	both	70 days	3	20.9	uV	3.7	6.41	electroretinography	cornea	plasmid delivery	54	days	pVAX2-rGDNF	scotopic a-wave ERG	108748	3131
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	138.93	uV	9.28	22.73	electroretinography	cornea	subretinal injection	2	days	dl-aaa + pbs	a-wave amplitude ERG	108523	3123
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours)	Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343.	rod electrophysiology trait	both	48 days	5	17.0	uV	18.0	40.25	electroretinography	cornea	subretinal injection	28	days	adenovirus	a-wave amplitude ERG	108381	3121
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	control condition then controlled exposure to darkness (for 12 hours)	Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343.	rod electrophysiology trait	both	62 days	5	8.9	uV	9.9	22.14	electroretinography			0		untreated control	a-wave amplitude ERG	108386	3121
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	15.03	uV	4.72	11.56	electroretinography	cornea	subretinal injection	7	days	dl-aaa	a-wave amplitude ERG	108393	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	108.63	uV	17.19	42.11	electroretinography	cornea	subretinal injection	7	days	dl-aaa	a-wave amplitude ERG	108395	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	143.17	uV	20.27	49.65	electroretinography	cornea	subretinal injection	7	days	dl-aaa	a-wave amplitude ERG	108397	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	224.32	uV	34.64	84.85	electroretinography	cornea	subretinal injection	7	days	dl-aaa	a-wave amplitude ERG	108403	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	162.07	uV	9.02	22.09	electroretinography	cornea	subretinal injection	10	days	dl-aaa	a-wave amplitude ERG	108419	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	202.5	uV	12.47	30.55	electroretinography	cornea	subretinal injection	10	days	dl-aaa	a-wave amplitude ERG	108420	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	27.7	uV	4.72	11.56	electroretinography	cornea	subretinal injection	10	days	dl-aaa	a-wave amplitude ERG	108423	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	218.83	uV	22.09	54.11	electroretinography	cornea	subretinal injection	30	min	pbs	a-wave amplitude ERG	108451	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	11	71.37	uV	8.23	27.3	electroretinography	cornea	subretinal injection	2	days	CHPG	a-wave amplitude ERG	108466	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	11	170.91	uV	16.52	54.79	electroretinography	cornea	subretinal injection	2	days	pbs	a-wave amplitude ERG	108474	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	11	201.55	uV	19.9	66.0	electroretinography	cornea	subretinal injection	2	days	pbs	a-wave amplitude ERG	108475	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	15.46	uV	4.1	10.04	electroretinography	cornea	subretinal injection	10	days	CHPG	a-wave amplitude ERG	108488	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	188.33	uV	15.56	38.11	electroretinography	cornea	subretinal injection	10	days	CHPG	a-wave amplitude ERG	108493	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	100.23	uV	12.78	31.3	electroretinography	cornea	subretinal injection	10	days	pbs	a wave amplitude ERG	108496	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	178.0	uV	12.3	30.13	electroretinography	cornea	subretinal injection	10	days	pbs	a wave amplitude ERG	108498	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	112.85	uV	11.14	27.29	electroretinography	cornea	subretinal injection	2	days	dl-aaa + MPEP	a-wave amplitude ERG	108514	3123
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	39 days	7	3.13	uV	1.81	4.79	electroretinography	cornea	subretinal injection	4	days	MPEP	a-wave amplitude ERG	108548	3123
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	39 days	7	24.79	uV	7.82	20.69	electroretinography	cornea	subretinal injection	4	days	MPEP	a-wave amplitude ERG	108552	3123
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	gene transfer of the lin-28 homolog B gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours)	Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343.	rod electrophysiology trait	both	62 days	5	11.0	uV	12.0	26.83	electroretinography	cornea	subretinal injection	42	days	adenovirus	a-wave amplitude ERG	108388	3121
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	190.68	uV	32.08	78.58	electroretinography	cornea	subretinal injection	7	days	dl-aaa	a-wave amplitude ERG	108402	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	7.62	uV	1.56	3.82	electroretinography	cornea	subretinal injection	10	days	dl-aaa	a-wave amplitude ERG	108422	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	149.83	uV	9.83	24.08	electroretinography	cornea	subretinal injection	10	days	dl-aaa	a-wave amplitude ERG	108425	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	202.33	uV	17.65	43.23	electroretinography	cornea	subretinal injection	10	days	dl-aaa	a-wave amplitude ERG	108426	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	88.5	uV	12.52	30.67	electroretinography	cornea	subretinal injection	30	min	CHPG	a-wave amplitude ERG	108442	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	216.67	uV	19.46	47.67	electroretinography	cornea	subretinal injection	30	min	CHPG	a-wave amplitude ERG	108445	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	11	5.17	uV	1.18	3.91	electroretinography	cornea	subretinal injection	2	days	CHPG	a-wave amplitude ERG	108464	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	11	137.5	uV	12.91	42.82	electroretinography	cornea	subretinal injection	2	days	CHPG	a-wave amplitude ERG	108469	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	166.85	uV	19.57	47.94	electroretinography	cornea	subretinal injection	10	days	CHPG	a-wave amplitude ERG	108492	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	30.66	uV	9.93	24.32	electroretinography	cornea	subretinal injection	10	days	pbs	a wave amplitude ERG	108495	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	208.5	uV	14.36	35.17	electroretinography	cornea	subretinal injection	2	days	dl-aaa + MPEP	a-wave amplitude ERG	108516	3123
RCS-rdy+ p+/LavRrrc	scotopic A wave amplitude of ERG waveform	DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	0 days	6	16.11	uV	3.41	8.35	electroretinography	cornea	subretinal injection	2	days	dl-aaa + pbs	a-wave amplitude ERG	108519	3123
Hsd:SD	scotopic A wave amplitude of ERG waveform	controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2)	Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.	rod electrophysiology trait	both	0 days	4	202.0	uV			electroretinography	cornea		0			scotopic a-wave ERG	108643	3128
RCS/N	scotopic A wave amplitude of ERG waveform	gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (21.6 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd x s/m2)	Deng WT, et al., Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904. doi: 10.1167/iovs.11-8831.	rod electrophysiology trait	not specified	62 days	6	175.0	uV	14.7	36.0	electroretinography	cornea	AAV8 injection	60	days	treated eye	scotopic a-wave amplitude ERG	108680	3129
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	39 days	7	18.53	uV	4.77	12.63	electroretinography	cornea	subretinal injection	4	days	MPEP	a-wave amplitude ERG	108538	3123
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	39 days	7	36.49	uV	10.37	27.44	electroretinography	cornea	subretinal injection	4	days	MPEP	a-wave amplitude ERG	108541	3123
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))	Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.	rod electrophysiology trait	both	39 days	7	31.96	uV	9.73	25.74	electroretinography	cornea	subretinal injection	4	days	MPEP	a-wave amplitude ERG	108553	3123
RCS-p+/LavRrrc	scotopic A wave amplitude of ERG waveform	gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2)	Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13.	rod electrophysiology trait	both	75 days	5	23.1	uV	4.0	8.94	electroretinography	cornea	plasmid delivery	59	days		scotopic a-wave ERG	108730	3131

Gene Annotator (Functional Annotation) unavailable	Gene Annotator (Annotation Distribution) unavailable	Variant Visualizer (Genomic Variants) unavailble Variant Visualizer (Genomic Variants) unavailable
Gene Annotator (Functional Annotation)	Gene Annotator (Annotation Distribution)	Variant Visualizer (Genomic Variants)

InterViewer (Protein-Protein Interactions) unavailable	Gviewer (Genome Viewer) unavailable	Variant Visualizer (Damaging Variants) unavailble Variant Visualizer (Damaging Variants) unavailable
InterViewer (Protein-Protein Interactions)	GViewer (Genome Viewer)	Variant Visualizer (Damaging Variants)

Gene Annotator (Annotation Comparison) unavailable	OLGA (Gene List Generator) unavailable
Gene Annotator (Annotation Comparison)	OLGA (Gene List Generator)	Excel (Download)

MOET (Multi-Ontology Enrichement) unavailable	GOLF (Gene-Ortholog Location Finder) unavailable
MOET (Multi-Ontology Enrichement)	GOLF (Gene-Ortholog Location Finder)

Create Name:

Description:

Send us a Message

Phenominer Database Results (111 results)